Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.
Morse
Michael A
MA
Duke University Medical Center, Division of Medical Oncology, Red Zone, Duke South Clinics, Durham, NC 27710, USA. michael.morse@duke.edu
D000906:Antibodies / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000096:biosynthesis / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology; D060908:CTLA-4 Antigen; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy; D000074324:Ipilimumab; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010330:Patents as Topic
D000906:Antibodies; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab